Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical firm Anesiva has announced a new exclusive Zingo marketing and distribution agreement, with Green Vision Company of Qatar, for several Middle Eastern countries.
Subscribe to our email newsletter
The agreement covers Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and United Arab Emirates. Green Vision will be responsible for obtaining and maintaining product registrations in the licensed territories, as well as sales and marketing in the region. Terms of the agreement include an upfront payment, regulatory and sales milestones and royalty payments.
Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system is approved in the US to provide topical local analgesia prior to peripheral IV insertions or blood draws in children three to 18 years of age.
John McLaughlin, Anesiva’s CEO, said: “This agreement further extends the potential markets for Zingo, a needle-free, local analgesic with a rapid onset of action, prior to peripheral venous access procedures in children, and is further validation of the unmet need Zingo addresses.”